SEC Tracker
Get the app

First Tracks Biotherapeutics TRAX

First Tracks Biotherapeutics registers securities for sale

Securities offering

Form
S-1
Filed
Importance
Notable
  1. Net loss of $33.37 million for Q2 2026
  2. Diluted EPS of -$0.95 for Q2 2026
  3. Cash and equivalents of $168.02 million as of June 30, 2026

Written from the S-1 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when First Tracks Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.